The race to come first to the billion-dollar food allergy market is heating up.
UK-based firm Allergy Therapeutics, which is listed on the London stock exchange, has announced in a press release that the US Food and Drug Administration (FDA) has given the company the green light to start a phase 1 trial of its peanut allergy vaccine in the US.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.